In today's overheated stock market, there aren't many undervalued names that you can invest in. However, pharmaceuticals happens to be one such industry rich in quality, undervalued, high-yield dividend growth names.
However, that doesn't mean you can blindly buy just any Big Pharma. Let's take a look at two titans of the industry, Merck (NYSE:MRK) and Pfizer (NYSE:PFE), to see why Pfizer is hands down the better dividend growth stock to buy right now.
Check, a first-of-its-kind payroll infrastructure startup whose mission is to make paying people simple, announced its public launch today with $35 million in Series B funding from Stripe and Thrive Capital.
MG+M The Law Firm (MG+M) is pleased to announce that it has elevated New York attorney Karina E. Murski
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that Matthew S. Rheingold has been elevated from
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that partners Thomas J. Snyder and Matheu D. Nunn
For partnerships, content marketing or advertising inquiries, please contact Edwin through his LinkedIn Profile
Connect© Copyright 2024 citybuzz
